NDA 200740 · Leadiant Biosci INC
Cystaran
Cysteamine Hydrochloride · Ophthalmic
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Oct 2, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
8 Phase 3, 2 recruiting
FAERS reports
458
96 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 21, 2026.
CYSTARAN ® is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. ( 1 )
Mechanism: Cysteamine acts as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2012 Original approval · Type 3 - New Dosage Form · priority review OrphanReviewSummary ReviewLetter
1 products under this application
- CYSTARAN · CYSTEAMINE HYDROCHLORIDE EQ 0.44% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cysteamine" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
National Eye Institute (NEI)NIH
NCT00001213 · 328 participants · Start Apr 1986 · Primary completion Jul 2013
Drug: Cysteamine · For: Cystinosis
Sites: Bethesda, Maryland
Mylan LaboratoriesIndustry
NCT00002110 · 300 participants
Drug: Cysteamine; Zidovudine · For: HIV Infections
Sites: Tampa, Florida; New Orleans, Louisiana; Stony Brook, New York · 6 sites in all
- Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in ChildrenPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01529268 · 169 participants · Start Jun 2012 · Primary completion Mar 2015
Drug: DR cysteamine bitartrate capsule · For: Nonalcoholic Fatty Liver Disease (NAFLD)
Sites: San Diego, California; San Francisco, California; Atlanta, Georgia · 10 sites in all
- Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal MelasmaPivotal-lookingStatus unknown
Cosmetique Active InternationalIndustry
NCT06278948 · 140 participants (planned) · Start Oct 6, 2023 · Primary completion Jun 2024
Drug: Group CYS · For: Melasma
Sites: Bangalore, India
- Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)Pivotal-lookingStatus unknown
University Hospital, AngersGovernment (non-federal)
NCT02101957 · 96 participants · Start Oct 2010 · Primary completion Jul 2015
Drug: RP103; Placebo · For: Huntington's Disease
Sites: Angers, France
NovaBiotics Ltd.Industry
NCT03000348 · 91 participants · Start Dec 2016 · Primary completion Apr 2018
Drug: Cysteamine; Placebo Oral Capsule · For: Cystic Fibrosis
Sites: Tucson, Arizona; San Francisco, California; Gainesville, Florida · 17 sites in all
- Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01197378 · 60 participants · Start Aug 27, 2010 · Primary completion Jun 26, 2017
Drug: Cysteamine Bitartrate Delayed-release Capsules · For: Cystinosis
Sites: San Francisco, California; Stanford, California; Atlanta, Georgia · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation141
- eye pain59
- ocular hyperaemia54
- photophobia36
- product dose omission issue19
- headache18
- nausea17
- vomiting17
- intentional product misuse13
- vision blurred13
- burning sensation11
- eye pruritus10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 12 |
| 2015 | 7 |
| 2016 | 35 |
| 2017 | 74 |
| 2018 | 62 |
| 2019 | 70 |
| 2020 | 83 |
| 2021 | 6 |
| 2022 | 23 |
| 2023 | 25 |
| 2024 | 28 |
| 2025 | 31 |
| 2026 | 1 |
Recalls
3 FDA enforcement reports for this application.
Sep 24, 2020 · Class III · Terminated
Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.
Apr 9, 2018 · Class III · Terminated
Subpotent drug: Out of specification for an active ingredient cysteamine hydrochloride.
Feb 14, 2018 · Class III · Terminated
Subpotent Drug: Out of specification for an active ingredient cysteamine hydrochloride.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cystaran (Cysteamine HCl)
2024 spending
$2.1M
Beneficiaries
24
242 claims
Per beneficiary
$87,118
$145.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,425,528 |
| 2021 | $0 |
| 2022 | $956,416 |
| 2023 | $2,015,519 |
| 2024 | $2,090,835 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acetaminophen.
Ameer B, Greenblatt DJ · Ann Intern Med 1977 · Clinical Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Interventions for paracetamol (acetaminophen) overdose.
Chiew AL, Gluud C, Brok J, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Hematopoietic Stem-Cell Gene Therapy for Cystinosis.
Barshop BA, Ball ED, Benador N, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Interventions for paracetamol (acetaminophen) overdoses.
Brok J, Buckley N, Gluud C · Cochrane Database Syst Rev 2002 · Systematic Review
- Interventions for paracetamol (acetaminophen) overdose.
Brok J, Buckley N, Gluud C · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis.
Kaur S, Sarma P, Kaur H, et al. · Am J Ophthalmol 2021 · Meta-Analysis, Systematic Review
Sponsor: Leadiant Biosci INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.